

October 04, 2013

BSE Limited
Corporate Service Department
1st Floor, New Trading Ring
Rotunda Building, P.J. Tower
Dalal Street, Fort
Mumbai - 400 001

The National Stock Exchange of India Ltd.
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 051

Dear Sirs,

Please be informed that the Board of Directors of the Company in its meeting held today accorded its approval to :

- a) Transfer and vest the two business undertakings namely Active Pharmaceuticals Ingredients (API) Business and Dosage Forms Business of the Company, together with all assets and liabilities on a going concern basis ; and
- b) Transfer of 18% shares of Jubilant Pharma Holdings Inc., USA (formerly Jubilant Life Sciences Holdings Inc.), and 77.65% shares of Jubilant Pharma NV, Belgium, held by the Company,

to a new company to be incorporated in India as a wholly owned subsidiary of Jubilant Pharma Limited, Singapore (which is a wholly owned subsidiary of the Company) for a total consideration of Rs.1145.10 crores, subject to the approval of shareholders of the Company and such other approvals and permissions as may be deemed necessary.

We are also enclosing a copy of the Press Release being issued today.

This is for your kind information and records.

Thanking you,

Yours faithfully,
for **JUBILANT LIFE SCIENCES LTD.**



Shyam S. Bhartia
Chairman & Managing Director

Encl: as above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Life Sciences Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd. Office:
Bhartiagram, Gajraula
Distt. Amroha-244 223,
UP, India



Jubilant Life Sciences Ltd.
1A, Sector 16A, Noida – 201301, India
Tel.: +91 120 4361000
www.jubl.com

Jubilant Life Sciences consolidates its Pharma Business under its Singapore Subsidiary

Noida (UP), India, Friday, October 4, 2013

Jubilant Life Sciences Ltd (JLL), an Integrated Pharmaceutical Life Sciences Company announced today that the Board has approved to transfer:

1. The API, Dosage Form businesses of JLL by way of a slump sale on a going concern basis and
2. Shares held by JLL in Jubilant Pharma Holding Inc, USA and Jubilant Pharma N.V., Belgium

to a wholly owned subsidiary of Jubilant Pharma Limited, Singapore (which is a wholly owned subsidiary of the Company) for a total consideration of Rs.1145.10 crores subject to the approval of the shareholders of the company and such other approvals and permissions as may be deemed necessary. In this regard, Jubilant Pharma Limited, Singapore has received approval from the Foreign Investment Promotion Board.

This will enable the Company to consolidate its API, Solid Dosage Form, Radiopharma, Allergenic extracts, Sterile Injectibles and Ointment, Cream and Liquid businesses (Pharma Business) under Jubilant Pharma Ltd, Singapore and to explore, identify and implement the options and opportunities of raising money including by way of listing the Pharma business for its growth and reduction of overall consolidated debt of the Company.

About Jubilant

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Generics, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery and Development. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of over 6200 multicultural people across the globe, the Company is committed to deliver value to its customers spread across 98 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.



For more information please contact:

For Investors

Ravi Agrawal
Jubilant Life Sciences Limited
Ph: +91-120 4361002
E-mail: ravi_agrawal@jubl.com

Siddharth Rangnekar
Citigate Dewe Rogerson
Tel: +91 22 6645 1209
E-mail: siddharth@cdr-india.com

For Media

Nidhi Malik
Jubilant Life Sciences Limited
Ph: +91-120 4361062
E-mail: nidhi_malik@jubl.com

Kanupriya Jain
Imprimis PR
Ph: +91 9811886757
E-mail: kjain@imprimispr.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.